Amitraz, Carfentrazone-ethyl, Ethephon, Malathion, Mancozeb, et al.; Proposed Tolerance Actions
| Federal Information & News Dispatch, Inc. |
SUMMARY:
EFFECTIVE DATE: Comments must be received on or before
ADDRESSES: Submit your comments, identified by docket identification (ID) number EPA-HQ-OPP-2014-0194, by one of the following methods:
* Federal eRulemaking Portal: http://www.regulations.gov. Follow the online instructions for submitting comments. Do not submit electronically any information you consider to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
* Mail: OPP Docket, Environmental Protection Agency Docket Center (
* Hand Delivery: To make special arrangements for hand delivery or delivery of boxed information, please follow the instructions at http://www.epa.gov/dockets/contacts.html.
Additional instructions on commenting or visiting the docket, along with more information about dockets generally, is available at http://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. The following list of North American Industrial Classification System (NAICS) codes is not intended to be exhaustive, but rather provides a guide to help readers determine whether this document applies to them. Potentially affected entities may include:
* Crop production (NAICS code 111).
* Animal production (NAICS code 112).
* Food manufacturing (NAICS code 311).
* Pesticide manufacturing (NAICS code 32532).
B. What should I consider as I prepare my comments for
1. Submitting CBI. Do not submit this information to
2. Tips for preparing your comments. When submitting comments, remember to:
i. Identify the document by docket ID number and other identifying information (subject heading,
ii. Follow directions. The Agency may ask you to respond to specific questions or organize comments by referencing a Code of Federal Regulations (CFR) part or section number.
iii. Explain why you agree or disagree; suggest alternatives and substitute language for your requested changes.
iv. Describe any assumptions and provide any technical information and/or data that you used.
v. If you estimate potential costs or burdens, explain how you arrived at your estimate in sufficient detail to allow for it to be reproduced.
vi. Provide specific examples to illustrate your concerns and suggest alternatives.
vii. Explain your views as clearly as possible, avoiding the use of profanity or personal threats.
viii. Make sure to submit your comments by the comment period deadline identified.
C. What can I do if I wish the agency to maintain a tolerance that the agency proposes to revoke?
This proposed rule provides a comment period of 60 days for any person to state an interest in retaining a tolerance proposed for revocation. If
II. Background
A. What action is the agency taking?
Also,
The proposed tolerance actions for mancozeb and malathion are consistent with the recommendations in their Reregistration Eligibility Decisions (REDs) of 2005 and 2009, respectively. As part of the tolerance reassessment process,
In REDs, Chapter IV on risk management, reregistration, and tolerance reassessment typically describes the regulatory position, cumulative safety determination, determination of safety for U.S. general population, and safety for infants and children. In particular, the human health risk assessment document which supports the RED describes risk exposure estimates and whether the Agency has concerns.
Explanations for proposed modifications in tolerances can be found in the RED document and in more detail in the
--This is a summary of a
Proposed rule.
CFR Part: "40 CFR Part 180"
RIN Number: "RIN 2070-ZA16"
Citation: "79 FR 40043"
Document Number: "EPA-HQ-OPP-2014-0194; FRL-9910-45"
Federal Register Page Number: "40043"
"Proposed Rules"
| Copyright: | (c) 2014 Federal Information & News Dispatch, Inc. |
| Wordcount: | 1479 |



Meeting the Health Care Needs of an Older Hispanic Population
Advisor News
- LTC: A critical component of retirement planning
- Middle-class households face worsening cost pressures
- Metlife study finds less than half of US workforce holistically healthy
- Invigorating client relationships with AI coaching
- SEC: Get-rich-quick influencer Tai Lopez was running a Ponzi scam
More Advisor NewsAnnuity News
- Trademark Application for “EMPOWER MY WEALTH” Filed by Great-West Life & Annuity Insurance Company: Great-West Life & Annuity Insurance Company
- Conning says insurers’ success in 2026 will depend on ‘strategic adaptation’
- The structural rise of structured products
- How next-gen pricing tech can help insurers offer better annuity products
- Continental General Acquires Block of Life Insurance, Annuity and Health Policies from State Guaranty Associations
More Annuity NewsHealth/Employee Benefits News
- New Managed Care Study Findings Have Been Reported by G. Martin Reinhart and Co-Researchers (Psychiatric Medication Prescribing by Nurse Practitioners and Physician Associates for Medicare Beneficiaries): Managed Care
- Data on Managed Care Reported by Researchers at American Dental Association (Early association of expanded Medicare dental benefits to dentist billing in Medicare): Managed Care
- Researchers to study universal health care, as Coloradans face $1 billion in medical debt
- Veteran speaks out on veterans mail-order drug bill
- National Life Group Selects FINEOS AdminSuite to Transform Living Benefit and Life Insurance Claims Operations
More Health/Employee Benefits NewsLife Insurance News